Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Journey Medical Corp (DERM)

Journey Medical Corp (DERM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,662
  • Shares Outstanding, K 17,432
  • Annual Sales, $ 63,130 K
  • Annual Income, $ -43,990 K
  • 60-Month Beta N/A
  • Price/Sales 0.66
  • Price/Cash Flow N/A
  • Price/Book 1.20
Trade DERM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.48
  • Prior Year 0.32
  • Growth Rate Est. (year over year) -206.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.29 +4.37%
on 10/05/22
3.69 -35.23%
on 09/15/22
-0.64 (-21.12%)
since 09/02/22
3-Month
2.29 +4.37%
on 10/05/22
4.36 -45.18%
on 08/11/22
-1.17 (-32.87%)
since 07/05/22

Most Recent Stories

More News
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

DERM : 2.39 (unch)
KMPH : 6.04 (-5.77%)
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...

DERM : 2.39 (unch)
FBIO : 0.8981 (+2.05%)
Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

SGTX : 0.5500 (+2.80%)
DERM : 2.39 (unch)
Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Molecular Templates Inc. (MTEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MTEM : 0.7998 (+8.80%)
DERM : 2.39 (unch)
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...

FBIO : 0.8981 (+2.05%)
DERM : 2.39 (unch)
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...

FBIO : 0.8981 (+2.05%)
DERM : 2.39 (unch)
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...

ACST : 0.6284 (+1.35%)
LPTH : 1.1400 (+1.79%)
RCAT : 1.6800 (-2.33%)
IONM : 0.6901 (-4.15%)
PYR : 1.1230 (-4.02%)
OSS : 3.23 (-1.82%)
MODD : 3.40 (-5.56%)
STRN : 1.4200 (+2.90%)
AEYE : 6.27 (+0.32%)
SMFL : 0.4200 (+3.04%)
LFMD : 2.13 (+0.47%)
SURG : 5.73 (+11.05%)
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the...

DERM : 2.39 (unch)
FBIO : 0.8981 (+2.05%)
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET...

FBIO : 0.8981 (+2.05%)
DERM : 2.39 (unch)
Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earnings...

DERM : 2.39 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Journey Medical Corporation is a commercial-stage pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Journey Medical Corporation is based in Scottsdale, Arizona.

See More

Key Turning Points

3rd Resistance Point 2.59
2nd Resistance Point 2.51
1st Resistance Point 2.45
Last Price 2.39
1st Support Level 2.31
2nd Support Level 2.23
3rd Support Level 2.17

See More

52-Week High 10.20
Fibonacci 61.8% 7.18
Fibonacci 50% 6.24
Fibonacci 38.2% 5.31
Last Price 2.39
52-Week Low 2.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar